Core Insights - Tilray Brands (TLRY) is set to report its first-quarter fiscal 2026 results on October 9, 2025, before market opening [1] - The company reported fourth-quarter fiscal 2025 adjusted earnings of 2 cents per share, exceeding the Zacks Consensus Estimate by 166.67% [1] - TLRY has beaten earnings estimates in two of the last four quarters and missed in the other two [1] Revenue and Earnings Estimates - The Zacks Consensus Estimate for revenues in the upcoming quarter is $206.8 million, indicating a 3.4% increase from the previous year [2] - The loss per share estimate is set at 3 cents, reflecting a 25% year-over-year increase [2] - Estimates for loss per share have remained unchanged at 3 cents over the past 30 days [3] Factors Influencing Performance - **Cannabis Segment**: In the fourth quarter of fiscal 2025, cannabis net revenues declined year-over-year due to a pause in vape and infused pre-roll categories and delays in international medical cannabis permits. However, international cannabis revenues reached a record high of $22.4 million, with Germany showing 134% growth [4] - **Tilray Medical**: The division introduced three new medical cannabis flower varieties in Italy, becoming the first authorized company to import and distribute its products there. A strategic partnership with Molteni aims to enhance the availability of Tilray Medical cannabis extracts in Italy, expected to boost top-line growth [5] Segment Performance Expectations - **Beverages**: The Beverages segment is anticipated to see a revenue decline due to SKU rationalization under Project 420. However, the Breckenridge Distillery brand is expected to show resilience in the bourbon sector [8][10] - **Wellness**: The Wellness segment is projected to experience a year-over-year revenue surge, driven by the growth of Manitoba Harvest Hemp Hearts and new product innovations [11] - **Distribution**: Distribution revenues, primarily from Tilray Pharma, are expected to grow due to changes in product mix [12] Earnings Outlook - Tilray Brands has an Earnings ESP of 0.00%, indicating no expected earnings surprise for the upcoming report [13] - The company currently holds a Zacks Rank of 3, suggesting a neutral outlook [13]

Core Insights - Breckenridge Distillery has launched a new product called Mountain Shot, which is a whiskey-based and malt-based beverage infused with maitake mushrooms, offering a unique drinking experience that reflects the spirit of the Rocky Mountains [1][6][4] Product Overview - Mountain Shot is available in whiskey-based and malt-based varieties, with the whiskey-based version produced at 69 proof and available in 750-milliliter, 1-liter bottles, and 100-milliliter resealable pouches. The malt-based version is produced at 30 proof and will be available in 100-milliliter pouches at convenience stores [3][4] - The infusion of maitake mushrooms adds a distinct mouthfeel and complexity to the drink, enhancing the overall flavor profile [3][5] Company Background - Breckenridge Distillery, founded in 2008, is known as the "World's Highest Distillery" and has received numerous awards for its spirits, including multiple accolades at the World Whiskies Awards and the San Francisco World Spirits Competition [7][8] - The distillery emphasizes craftsmanship and innovation, aiming to challenge conventions in whiskey production while honoring traditional methods [4][6] Market Positioning - Mountain Shot is positioned as a beverage for adventurous consumers who enjoy outdoor activities and social gatherings, making it suitable for consumption in various settings, such as mountainsides or bars [4][6] - The product is part of a broader strategy to connect with consumers by offering a unique and portable drinking experience that aligns with their lifestyle [5][6]